Related by context. All words. (Click for frequent words.) 78 hepatocellular carcinoma 71 advanced hepatocellular carcinoma 69 metastatic renal cell carcinoma 69 pancreatic neuroendocrine tumors 69 basal cell carcinoma BCC 69 leukemia CLL 69 epithelial tumors 68 carcinoid tumors 68 leukemia ALL 68 systemic lupus erythematosus SLE 68 colorectal carcinoma 68 gastric cancers 68 pheochromocytoma 68 GISTs 68 recurrent glioblastoma multiforme 68 adenocarcinomas 68 recurrent NSCLC 68 acute myelogenous leukemia AML 68 glioblastoma multiforme GBM 67 malignant pleural mesothelioma 67 stage IIIB 67 sorafenib Nexavar 67 gastric adenocarcinoma 67 cell lymphoma CTCL 67 nonmetastatic 67 renal cell carcinoma 67 Hepatocellular Carcinoma HCC 67 cutaneous melanoma 67 renal tumors 67 tumors GIST 67 hepatocellular cancer 67 prostate cancer CaP 67 nasopharyngeal carcinoma 67 pancreatic adenocarcinoma 67 myeloproliferative disorders 67 leukemia AML 67 superficial bladder cancer 67 invasive candidiasis 66 neoplasm 66 metastatic gastric 66 ADPKD 66 receptor tyrosine kinase inhibitor 66 MALT lymphoma 66 metastatic GIST 66 allogeneic bone marrow 66 erlotinib Tarceva ® 66 metastatic neuroendocrine tumors 66 metastatic RCC 66 essential thrombocythemia 66 soft tissue sarcomas 66 NSCLC 66 Apaziquone 66 colorectal cancer CRC 66 liver metastases 66 gastric cancer 66 medullary thyroid cancer 66 cervical carcinoma 66 prostate cancer PCa 66 acute leukemias 66 CYT# potent vascular disrupting 66 Hodgkin lymphoma HL 66 refractory multiple myeloma 66 gefitinib Iressa 66 CMV disease 66 DLBCL 66 systemic lupus erythematosus 66 ABCB1 66 mRCC 66 papillary renal cell carcinoma 66 HNSCC 66 metastatic colorectal 65 gastrointestinal stromal tumor GIST 65 NMIBC 65 cholangiocarcinoma 65 colorectal adenocarcinoma 65 situ CIS 65 familial amyloidotic polyneuropathy FAP 65 Sezary syndrome 65 hepatic metastases 65 pancreatic NET 65 prostate cancer CRPC 65 SCCHN 65 neuroendocrine tumors 65 multiple myeloma MM 65 astrocytomas 65 pulmonary metastases 65 Malignant Melanoma 65 adenocarcinoma 65 transplantation HSCT 65 relapsing multiple sclerosis 65 neuroendocrine cancers 65 unresectable 65 fallopian tube carcinoma 65 HCV infection 65 paraganglioma 65 lung adenocarcinoma 65 malignant neoplasms 65 serous ovarian cancer 65 castration resistant prostate cancer 65 thromboembolic events 65 cell lymphoma ALCL 65 ovarian carcinoma 65 nucleoside analog 65 polycythemia vera PV 65 distant metastasis 65 myeloproliferative diseases 65 depsipeptide 65 colon carcinoma 65 biliary tract cancer 65 acute promyelocytic leukemia APL 65 lymphoma CTCL 65 urothelial carcinoma 65 gastric carcinoma 65 gastrointestinal stromal tumor 64 thymoma 64 advanced NSCLC 64 prostate adenocarcinoma 64 recurrent ovarian cancer 64 PCa 64 chronic lymphocytic leukemia CLL 64 Leukemias 64 essential thrombocythemia ET 64 candidemia 64 Doxil ® 64 renal cell carcinomas 64 prostate carcinoma 64 IV NSCLC 64 carcinoma 64 neoplasia 64 taxane therapy 64 chronic HBV infection 64 squamous cell carcinoma SCC 64 metastatic malignant 64 docetaxel Taxotere ® 64 bevacizumab Avastin ® 64 bladder cancers 64 syngeneic 64 imatinib Gleevec 64 Cholangiocarcinoma 64 PCNSL 64 Cutaneous T 64 Gastric cancer 64 graft dysfunction 64 lupus nephritis 64 solid tumors 64 carcinoid 64 BRAF mutation 64 urothelial cancer 64 intestinal metaplasia 64 Fludara ® 64 lobular carcinoma 64 cell lymphomas 64 EGFR HER2 64 breast carcinoma 64 myeloproliferative 64 Myelodysplastic Syndrome MDS 64 relapsed refractory multiple myeloma 64 grade cervical intraepithelial 64 uveal melanoma 64 bendamustine 64 Advanced Renal Cell 64 histone deacetylase inhibitor 64 myelofibrosis polycythemia vera 64 carcinomas 64 metastatic malignant melanoma 63 bone metastasis 63 neoadjuvant therapy 63 PAOD 63 Enzastaurin 63 hypereosinophilic syndrome 63 peritoneal carcinomatosis 63 cell carcinomas 63 pancreatic carcinoma 63 gastrointestinal stromal tumors GIST 63 basal cell nevus syndrome 63 resectable 63 Hepatocellular Carcinoma 63 advanced metastatic renal 63 metastatic bladder 63 lymphoid malignancies 63 BCG refractory 63 brain metastases 63 Chronic lymphocytic leukemia 63 liposomal amphotericin B 63 Cloretazine 63 thalidomide Thalomid 63 myelodysplastic myeloproliferative diseases 63 Hodgkin lymphoma NHL 63 cutaneous T cell 63 MGUS 63 proteasome inhibitor 63 recurrent GBM 63 Glioma 63 malignant lymphoma 63 Genasense ® 63 Mitomycin C 63 cutaneous T 63 hematologic disorders 63 PsA 63 malignant lymphomas 63 PNET 63 breast carcinomas 63 hepatocellular carcinomas 63 acute myeloid 63 metastases 63 castrate resistant prostate cancer 63 metachronous 63 endometrial hyperplasia 63 non squamous NSCLC 63 SSc 63 Gleevec resistant 63 esophageal squamous cell carcinoma 63 tumor xenograft models 63 Akt inhibitor 63 recurrent glioblastoma 63 SJIA 63 Gorlin syndrome 63 LHRH receptor positive 63 refractory AML 63 transthyretin amyloidosis 63 metastatic pancreatic 63 severe neutropenia 63 nonsmall cell lung cancer 63 PKC# 63 BR.# 63 Waldenstrom macroglobulinemia 63 Glioblastoma multiforme 63 Glioblastoma Multiforme 63 lymphoproliferative disorders 63 EGFR mutation 63 Irinotecan 63 Epstein Barr virus EBV 63 fallopian tube cancers 63 HER2 positive metastatic breast 63 T2DM 63 cisplatin chemotherapy 63 epithelial ovarian cancer 63 metastatic colorectal cancer 63 immunocompetent 63 bladder carcinoma 63 acute GvHD 63 Multiple Myeloma MM 63 myelofibrosis MF 63 tumor lysis syndrome 63 virus HCV infection 63 xenograft models 62 colorectal liver metastases 62 esophageal carcinoma 62 juvenile idiopathic arthritis 62 dasatinib Sprycel 62 unresectable stage 62 lymphomas 62 mutational status 62 neoadjuvant 62 bronchogenic carcinoma 62 sarcomas 62 imatinib resistant 62 HDACi 62 leiomyomas 62 non resectable 62 systemic fungal infections 62 epithelial ovarian 62 peritoneal cancer 62 chronic myeloid 62 liver resection 62 lung carcinomas 62 anti angiogenic therapy 62 myelodysplastic syndrome MDS 62 refractory chronic lymphocytic 62 lung metastases 62 skeletal metastases 62 Papillary 62 chemoradiotherapy 62 polycythemia vera essential thrombocythemia 62 CMV infection 62 breast cancer subtypes 62 locoregional 62 dasatinib Sprycel ® 62 Proxinium TM 62 neoadjuvant treatment 62 idiopathic myelofibrosis 62 acute coronary syndromes ACS 62 adjuvant therapy 62 ZACTIMA 62 nodal metastasis 62 CA4P 62 HER2 positive cancers 62 histologically confirmed 62 neoadjuvant chemotherapy 62 MGd 62 mycosis fungoides 62 Myelofibrosis 62 cilengitide 62 liver metastasis 62 cervical intraepithelial neoplasia 62 HER2 overexpression 62 Diffuse Large B 62 Nexavar tablets 62 androgen independent 62 relapsing remitting multiple sclerosis 62 metastatic liver 62 EGFR expressing 62 FLT3 62 CD# monoclonal antibody 62 axitinib 62 oral squamous cell 62 pan HDAC inhibitor 62 gefitinib 62 relapsed ovarian cancer 62 secondary hyperparathyroidism 62 myelodysplastic syndromes MDS 62 lymphocytosis 62 sorafenib tablets 62 malignant pleural mesothelioma MPM 62 HER2 positive 62 fluoropyrimidine 62 Zolinza 62 Glioblastoma multiforme GBM 62 Idiopathic Pulmonary Fibrosis 62 histologies 62 relapsing remitting MS RRMS 62 adriamycin 62 Kit CD# positive 62 multikinase inhibitor 62 Xanafide 62 gemcitabine carboplatin 62 colorectal adenoma 62 Vidaza azacitidine 62 carcinoma HCC 62 hepatitis C HCV 62 stage IIIb IV 62 histologic subtype 62 pain palliation 62 metastatic melanoma 62 phase IIb clinical 62 CLL 62 trabectedin 62 lung pancreatic 62 AEG# 62 histone deacetylase HDAC inhibitor 62 subependymal giant cell 62 IL# PE#QQR 62 refractory NSCLC 62 extracranial 62 myeloproliferative neoplasms 62 hepatoma 62 malignancies 62 small lymphocytic lymphoma 62 vinca alkaloid 62 mycophenolate mofetil 62 metastatic cancers 62 AA amyloidosis 61 geographic atrophy 61 Tarceva TM 61 micrometastases 61 chronic eosinophilic leukemia 61 PEGylated interferon beta 1a 61 symptomatic BPH 61 pediatric acute lymphoblastic 61 ErbB2 positive 61 Squamous 61 multicentric 61 adenomatous 61 Cell Lymphoma 61 metastatic lesions 61 fibrotic disease 61 lymphoma subtypes 61 Barrett esophagus BE 61 operable breast cancer 61 breast pancreatic 61 mTOR mammalian target 61 cell acute lymphoblastic 61 HBeAg negative 61 mCRC 61 paragangliomas 61 ductal carcinomas 61 MELAS 61 HeFH 61 vWD 61 Chronic Lymphocytic Leukemia CLL 61 Candida infection 61 B CLL 61 Surgical resection 61 anterior uveitis 61 SHPT 61 EGFR inhibitors 61 Chronic Myelogenous Leukemia CML 61 superficial basal cell carcinoma 61 assessing T DM1 61 unresectable locally advanced 61 Severe Primary IGFD 61 invasive ductal 61 completely resected 61 TACE 61 non metastatic osteosarcoma 61 prostate carcinomas 61 antitumor effect 61 histological subtype 61 SUTENT 61 hepatorenal syndrome 61 ToGA 61 alkylating agent 61 nonmelanoma skin cancers 61 recurrent glioblastoma multiforme GBM 61 Carcinoma 61 Telintra 61 imatinib Gleevec ® 61 node metastases 61 gastrointestinal stromal tumors GISTs 61 Acute Myeloid Leukemia AML 61 GIST 61 distant metastases 61 AAT deficiency 61 papillary thyroid carcinoma 61 refractory CTCL 61 activating mutations 61 colorectal liver 61 Amrubicin 61 stage IIIA 61 neoplasias 61 neoplasms 61 chemotherapeutic regimen 61 liver transplant recipients 61 refractory CLL 61 hypercalcemia 61 CLL SLL 61 carcinoids 61 unresectable tumors 61 recurrent malignant glioma 61 inhibitor RG# 61 cetuximab Erbitux R 61 premalignant 61 follicular lymphoma 61 vinca alkaloids 61 cytogenetic abnormalities 61 sorafenib 61 bleomycin 61 randomized Phase III 61 K ras mutations 61 Renal cell carcinoma 61 refractory acute myeloid 61 Relapsed Refractory 61 imatinib mesylate 61 cytoreduction 61 relapsed MM 61 atypical hemolytic uremic syndrome 61 MAGE A3 ASCI 61 Fas ligand 61 vandetanib 61 transplantation HCT 61 squamous 61 Fludara 61 novel VDA molecule 61 cancer mCRC 61 epithelioid 61 Pemetrexed 61 Acute Myeloid Leukaemia AML 61 adenoma 61 ALK inhibitor 61 hyperplastic 61 pegylated liposomal doxorubicin 61 osteosarcomas 61 fosbretabulin 61 posaconazole 61 acute humoral rejection 61 lymph node metastases 61 oral leukoplakia 61 BAY #-# 61 antibody MAb 61 tuberous sclerosis TS 61 STRIDE PD 61 locoregional recurrence 61 AA Amyloidosis 61 sunitinib 61 Epratuzumab 61 INCB# [003] 61 platelet inhibitor 61 WT1 61 medulloblastoma 61 ON #.Na 61 situ LCIS 61 malignant neoplasm 61 AVASTIN 61 haematopoietic 61 somatostatin analogue 61 PNP inhibitor 61 medulloblastomas 61 sunitinib malate 61 lung fibrosis 61 cutaneous squamous cell carcinoma 61 docetaxel chemotherapy 61 CEQ# 61 hepatic metastasis 61 allogeneic stem cell 61 endometrial carcinoma 61 BRAF V#E mutation 61 macroalbuminuria 61 Glioblastoma 61 gastrointestinal stromal tumors 60 mutated KRAS gene 60 Neoadjuvant 60 juvenile idiopathic arthritis JIA 60 precursor lesions 60 cisplatin resistant 60 targeting CD# 60 neoplastic lesions 60 Endometrial 60 hormone receptor negative 60 immunomodulatory therapy 60 radiation sensitizer 60 severe oral mucositis 60 Follicular Lymphoma 60 Velcade bortezomib 60 pancreatic ductal adenocarcinoma 60 mucinous 60 resistant ovarian cancer 60 cytoreductive nephrectomy 60 tyrosine kinase inhibitors TKIs 60 Hepatocellular carcinoma HCC 60 prognostic markers 60 atherosclerotic lesions 60 adjuvant radiotherapy 60 extranodal 60 cell adhesion molecule 60 solar keratosis 60 pertuzumab 60 elacytarabine 60 recurrent colorectal cancer 60 neuroendocrine carcinoma 60 huN# DM1 60 EGFR mutation positive 60 stage IIIB IV 60 EpCAM 60 endometrial cancers 60 Eculizumab 60 seminoma 60 hepatic fibrosis 60 GNAQ 60 ELACYT 60 HRPC 60 renal carcinoma 60 benign prostatic hypertrophy BPH 60 mCRC patients 60 amrubicin 60 sunitinib Sutent 60 ximelagatran 60 atypical Hemolytic Uremic Syndrome 60 heavily pretreated 60 leiomyoma 60 non squamous 60 selective inhibitor 60 chronic granulomatous disease 60 ponatinib 60 EGFR tyrosine kinase inhibitors 60 efalizumab 60 Neulasta ® 60 GW# [003] 60 mediated apoptosis 60 pleomorphic 60 EGFR mutations 60 Li Fraumeni Syndrome 60 HER2 negative 60 colorectal tumors 60 pegfilgrastim 60 glioblastoma 60 bladder ovarian 60 cirrhosis liver failure 60 diabetic nephropathy 60 mTOR inhibitors 60 relapsed leukemia 60 Natalizumab 60 Akt activation 60 autoantibody positive 60 prognostic variables 60 VELCADE melphalan 60 cell chronic lymphocytic 60 Extensively drug 60 Aplidin 60 kidney urologic 60 Afatinib 60 Omacetaxine 60 ANCA associated 60 papillary carcinoma 60 Tyrima 60 liver cancer 60 Metastatic breast cancer 60 Vectibix monotherapy 60 metastatic prostate cancer 60 advanced adenomas 60 lenalidomide dexamethasone 60 romidepsin 60 oral candidiasis 60 nasopharyngeal cancer 60 nonalcoholic steatohepatitis NASH 60 androgen deprivation 60 Atypical Hemolytic Uremic Syndrome 60 TKI therapy 60 KRAS mutations 60 refractory gout 60 registrational trial 60 diabetes mellitus DM 60 Vorinostat 60 MYCN amplification 60 node metastasis 60 monoclonal anti 60 hypoparathyroidism 60 systemic anaplastic large 60 cell lymphoma PTCL 60 TNF Tumor Necrosis Factor 60 indolent NHL 60 Bronchiectasis 60 chemoembolization 60 Lymphocytic 60 IMA# 60 LHRH antagonists 60 malignancy 60 Vidofludimus 60 BCG refractory carcinoma 60 Pharmacokinetics PK 60 Dacogen decitabine 60 Yondelis ® 60 ATTR 60 Clostridium difficile associated 60 panobinostat 60 Epidermal Growth Factor Receptor 60 vemurafenib 60 Nexavar sorafenib 60 metastatic cancer 60 mesotheliomas 60 promoter methylation 60 octreotide LAR 60 Voreloxin 60 Adjuvant chemotherapy 60 demonstrated antitumor activity 60 sarcomatoid 60 cell malignancies 60 cetuximab Erbitux ® 60 oesophageal adenocarcinoma 60 castration resistant 60 systemic juvenile idiopathic 60 imatinib resistance 60 metastatic HRPC 60 chronic myeloid leukemia CML 60 afatinib 60 Metastatic 60 BARACLUDE ® 60 relapsed multiple myeloma 60 proteasome inhibitor bortezomib 60 synovial sarcoma 60 antiangiogenic therapy 60 ara C 60 rFVIIa 60 refractory indolent non 60 gemcitabine chemotherapy 60 opioid induced constipation OIC 60 irreversible inhibitor 60 multicenter Phase II 60 haematological toxicity 60 vinorelbine 60 fluvastatin 60 TNF blocker therapy 60 PEGylated anti 60 metastatic disease 60 follicular lymphoma FL 60 astrocytoma 60 Mitoxantrone 60 esophageal gastric 60 metastatic carcinoma 60 variceal bleeding 60 pDC 60 SSc patients 60 MAGE A3 60 HoFH 60 terlipressin 60 tyrosine kinase inhibitor 60 advanced adenoma 60 cell carcinoma 60 relapsed SCLC 60 Aflibercept 60 noninfectious uveitis 60 evaluating tivozanib 60 voriconazole 60 chlorambucil 60 nephrotoxicity 60 castrate resistant 60 Asymptomatic 60 Renal Cell Carcinoma RCC 60 BRAF mutations 60 TNF antagonist 60 atherothrombosis 60 PD LID 60 sPLA2 60 MabCampath 60 micafungin 60 lung metastasis 60 urothelial bladder cancer 59 cytotoxic chemotherapy 59 protein tyrosine phosphatase 1B 59 choroidal neovascularization 59 CTEPH 59 recurrent VTE 59 lymphoproliferative disorder 59 PDX pralatrexate 59 preoperative chemotherapy 59 ALN TTR 59 idiopathic pulmonary fibrosis IPF 59 T1a 59 CRVO 59 capecitabine Xeloda R 59 tumor recurrence 59 prostate cancer HRPC 59 leukaemias 59 sporadic ALS 59 receptor blocker 59 TMC# C# 59 Rheumatoid Arthritis RA 59 decitabine 59 refractory colorectal cancer 59 hypervascular tumors 59 precancerous cervical lesions 59 Epstein Barr Virus EBV 59 OPAXIO 59 VEGF inhibitors 59 alvespimycin 59 ALK mutations 59 NSCLC tumors 59 Idiopathic Pulmonary Fibrosis IPF 59 ductal breast cancer 59 patientswith 59 adenomatous polyps 59 nonmelanoma skin cancer 59 pancreatic islet cell 59 relapsing remitting 59 glomerulonephritis 59 HQK 59 thyroid carcinoma 59 squamous cell carcinoma 59 HCV genotype 59 Glioblastoma Multiforme GBM 59 Hematologic 59 neoplastic 59 Janus kinase 59 Hsp# Inhibitor 59 anticancer compound 59 invasive fungal infections 59 Daclizumab 59 Severe Sepsis 59 Seliciclib 59 epithelial cancers 59 JAK2 59 haematologic malignancies 59 ixabepilone 59 nucleoside analogue 59 prognostic indicator 59 HSP# inhibitor 59 microsphere therapy 59 DU #b 59 ADI PEG 59 erythematosus 59 T1DM 59 TORISEL 59 CIMZIA TM certolizumab pegol 59 oral prodrug 59 IV melanoma 59 transitional cell carcinoma 59 IFN beta 59 Adenocarcinoma 59 mTOR inhibitor 59 plus gemcitabine 59 atrophic gastritis 59 clinically localized prostate 59 transurethral resection 59 hormone receptor positive 59 pleural mesothelioma 59 cytoreductive surgery 59 idiopathic PAH 59 Cloretazine R 59 Chronic Prostatitis 59 interferon beta therapy 59 vidofludimus 59 metastatic relapsed 59 PARP inhibitor 59 NPM1 59 Non Alcoholic Steatohepatitis 59 temsirolimus 59 Aurora kinase 59 MYLOTARG 59 haematological cancers 59 effector function 59 chemotherapy induced neutropenia 59 leiomyosarcoma 59 2 methoxyestradiol 59 Evoltra ® 59 rituximab Rituxan 59 portal vein thrombosis 59 Paraplatin ® 59 T#I mutation 59 Systemic Lupus Erythematosus 59 monocytic 59 lung tumors 59 idiopathic thrombocytopenic purpura ITP 59 Bezielle 59 YONDELIS 59 CHOP chemotherapy 59 trans retinoic acid 59 hepatic cirrhosis 59 pulmonary metastasis 59 invasive ductal carcinoma 59 invasive aspergillosis 59 Pralatrexate 59 FOLOTYN ® 59 SIR Spheres microspheres 59 hypoxia inducible factor 59 colorectal adenomas 59 hepatoblastoma 59 platinum refractory 59 Acute Coronary Syndromes ACS 59 velafermin 59 R sorafenib tablets 59 T#I [002] 59 chimeric monoclonal antibody 59 Acute lymphoblastic leukemia 59 HBeAg positive 59 dacarbazine DTIC 59 ribavirin Copegus ® 59 epirubicin 59 seliciclib 59 HMG CoA reductase inhibitors 59 induced macular edema 59 premalignant lesions 59 pelvic lymphadenectomy 59 membranous nephropathy 59 Squalamine 59 Aviptadil 59 ankylosing spondylitis AS 59 TTR gene 59 squamous cell carcinomas 59 p# biomarker 59 TTR amyloidosis 59 obscure gastrointestinal bleeding 59 antiproliferative effects 59 RNAi therapeutic targeting 59 gastrointestinal cancers 59 invasive lobular carcinoma 59 tigecycline 59 hematologic malignancies 59 KRAS wild 59 liver fibrosis 59 pediatric Crohn disease 59 urothelial 59 PXD# 59 glucocorticoid induced osteoporosis 59 S. aureus bacteremia 59 myelomas 59 ependymoma 59 pancreatic cancers 59 Acute Myelogenous Leukemia AML 59 apoptotic pathway 59 panitumumab Vectibix 59 chronic myocardial ischemia 59 HER2 expression 59 HER2 positive breast cancer 59 5FU 59 Carcinoid tumors 59 VUR 59 pamidronate 59 prostate cancer mCRPC 59 bexarotene 59 BRAF V#E 59 c KIT 59 autologous SCT 59 R lenalidomide 59 Raf MEK ERK 59 myeloproliferative disorder 59 Gliomas 59 CTAP# Capsules 59 severe hypersensitivity reactions 59 medically inoperable 59 Pafuramidine 59 GIST tumors 59 hyperplasia BPH 59 Trastuzumab 59 Non Hodgkin lymphoma 59 Toxicities 59 total thyroidectomy 59 IL 1ß 59 imatinib therapy 59 metastatic CRC 59 localized renal 59 thromboembolic complications 59 metastatic tumors 59 Herceptin trastuzumab 59 prognostic biomarker 59 prognostic factor 59 cisplatin gemcitabine 59 daunorubicin 59 nab paclitaxel 59 monogenic 59 CALGB # [002] 59 HGPIN 59 cediranib 59 satraplatin Phase 59 chemotherapy induced thrombocytopenia 59 esophageal candidiasis 59 metastatic renal cell 59 cardiac dysfunction 59 PC# cells 59 Lupus nephritis 59 biochemical recurrence 59 CC genotype 59 adecatumumab 59 CINTREDEKIN BESUDOTOX 59 anti leukemic 59 JAK inhibitors 59 SCH # 59 ADAMTS# 59 INC# 59 adrenocortical cancer 59 metastatic lung cancer 59 prostate TURP 59 Basal cell 59 Chronic Lymphocytic Leukemia 59 ALA PDT 59 tumor subtypes 59 disease CDAD 59 chemotherapeutic agent 59 huC# DM4 59 invasive carcinomas 59 leukemia APL 59 chronic HBV 59 LUX Lung 59 gastrointestinal perforation 59 poly ADP ribose polymerase 59 CDKN2A 59 basal cell carcinomas 59 chemoresistant 59 thromboembolism 59 chronic HCV 59 allogeneic hematopoietic stem cell 59 Albuferon TM 59 metastatic castration resistant 59 anaplastic lymphoma kinase 59 TACI Ig 59 Diabetic nephropathy 59 Ceflatonin 59 Leydig cell 59 TP# mutations 59 solithromycin 59 anaplastic 59 idarubicin 59 Dasatinib 59 HCV SPRINT 59 actinic keratosis 59 Myelodysplastic Syndrome 59 refractory cutaneous T 59 Chronic Myeloid Leukemia CML 59 neuroblastomas 59 Renal impairment 59 Non Hodgkin 59 Sym# 59 pancreatic neuroendocrine 59 non Hodgkin lymphomas 59 acute promyelocytic leukemia 59 GvHD 59 nutlin 3a 59 unresectable liver cancer 59 NF1 59 aHUS 59 coinfected patients 59 Anaplastic 59 IgG1 antibody 59 eIF 4E 59 G#DT 59 alkylating agents 59 neratinib 59 PTLD 59 chemotherapeutic regimens 58 Romidepsin 58 cervical neoplasia 58 intrahepatic 58 HCV infected 58 nucleoside analogues 58 HCV infections 58 ERBB2 58 cinacalcet 58 Uricase PEG 58 Annamycin 58 arthritis PsA 58 herpesviruses 58 docetaxel Taxotere R 58 systemic ALCL 58 chronic GVHD 58 Blinatumomab 58 trastuzumab Herceptin R 58 ALCL 58 SIR Spheres 58 oblimersen 58 denileukin diftitox 58 NSABP